The COVID-19 pandemic fundamentally changed pharmaceutical manufacturing approaches – demonstrating it’s possible to dramatically compress traditional timelines while maintaining quality standards. At CDMO Live 2025, Fabrice Le Garrec, founder of the OSICS network, shared lessons learned from his experience during
Simon Kucher opened CDMO Live 2025 in Rotterdam by unveiling brand new research developed in partnership with PharmaSource. The comprehensive study, presented by Kaan-Fabian Kekec and Clarita Simon, mapped the evolving landscape of CDMO-sponsor partnerships based on insights from over
CDMO Live 2025 kicked off last night with a vibrant Welcome Reception at Rotterdam’s World Trade Center, sponsored by Syngene. The reception marked the perfect start to Europe’s premier contract manufacturing event, where over the next two days, attendees will
“The pharmaceutical industry is very good at being reactive. If something happens, they have very clear processes, but they’re not so good at essentially anticipating certain changes.” – David Schneider David Schneider, Founder & CEO of Qualifyze, brings more than
As biopharma manufacturing leaders prepare to gather in Rotterdam for CDMO Live 2025, six critical themes have emerged. These six issues will form the new manufacturing playbook that will be essential for navigating the unprecedented volatility reshaping our industry. 1.
At this time of increasing geopolitical tensions, Claire Greenaway – Chemical, Biological, Radiological and Nuclear (CBRN) Delivery Team at the UK Ministry of Defence – explains why she is attending CDMO Live and what opportunities are for collaboration. Claire Greenaway’s
“In Big Pharma, innovation is often stifled because the bureaucracy and mindset completely kills creativity and intuition needed for discovery. That’s why they now prefer to allocate their early-phase resources to smaller biotechs,” explains Julien Laizé, sharing candid insights about
“We are privately owned by a Trust, which means all our profits are reinvested in the company. This translates to steady growth – maybe slower compared to other service providers, but we’re quite proud of that steady growth,” explains Franciane
“AI doesn’t have to be the first port of call. Many organisations still need to focus on the paper-to-glass journey before they can think about more advanced technologies” – Vishnu Dwadasi Vishnu Dwadasi, Director of Life Sciences at West Monroe,
“Our goal is to be more than a service provider. We aim to be a strategic partner that grows with our clients from bench to bedside.” – Dr. Jim Li Dr. Jim Li, President of CMC Solutions at BioDuro, brings
Stay ahead of trends and best practices
Exclusive downloads and podcasts
Get invites to special events and meetups 
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
